ClinicalTrials.gg
CompletedNCT01328444COPDUpdated Oct 11, 2017Results posted

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

A Phase 3 interventional study of GSK 573719 +GW642444 125/25 and GSK573719 + GW642444 62.5/25 in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 31 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-10-11.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
349
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 3 under way, 1 of them phase 3. vilanterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
20th of 48
349 · median 168
Started
2011
with 7 others
Phase 3
19 of 48
none open now
Registered
22nd of 48
by date
Lead sponsor
41 of 48
GlaxoSmithKline

Among the 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive, this one is the 20th largest by enrollment, is one of 8 that started in 2011, is one of 19 in phase 3, and was the 22nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About vilanterol

vilanterol: first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI)

Read the detailed description

Expiratory airflow limitation is the most obvious physiological change associated with chronic obstructive pulmonary disease (COPD). A consequence of airflow limitation is gas trapping as expiration becomes flow limited. This may occur at rest with more severe airway obstruction and is most evident during exercise as lung emptying is reduced and increased ventilation does not allow full expiration. This increased gas trapping or hyperinflation is the cause of much of the increased work of breathing, dyspnea, and exercise intolerance in subjects with COPD (O'Donnell 1997; O'Donnell, 1993). Spirometric measurement of airflow limitation, particularly as assessed by forced expiratory volume in one second (FEV1), is commonly used for the diagnosis of and assessment of response to pharmacotherapeutic intervention in COPD. However, changes in FEV1 may not fully predict symptomatic responses and alternative measures of lung hyperinflation such as exercise tolerance and exertional dyspnea may be more sensitive to therapeutic intervention and/or more clinically relevant than FEV1 [O'Donnell1999; Bauerle, 1998; O'Donnell, 1998; Officer, 1998]. GSK573719/GW642444 Inhalation Powder, a combination of the long-acting muscarinic antagonist (LAMA) bronchodilator GSK573719 and the long-acting beta2-agonist (LABA) bronchodilator GW642444, is in development for the maintenance treatment of airflow obstruction associated with COPD. Development of this product is supported by studies showing improvement in lung function with similar safety when use of combinations of long-acting bronchodilators with different mechanisms of action are compared with single bronchodilator therapy [van Noord 2005; van Noord van Noord 2006; Tashkin 2008]. Previous studies have demonstrated that treatment with short- and long-acting bronchodilators including ipratropium, tiotropium, and salmeterol reduces resting lung hyperinflation as measured by functional residual capacity (FRC), residual volume (RV), and inspiratory capacity (IC), with associated improvements in exercise endurance time and exertional dyspnoea in subjects with COPD [Ayers, 2001; O'Donnell 1998; O'Donnell 2004; Pepin 2005; Pepin 2007; Ramirez-Venegas 1997]. However, the effect of combined LAMA/LABA therapy on these measures is not well characterized.

This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI) Approximately 312 subjects with moderate/severe chronic obstructive pulmonary disease (COPD) will be randomised in order to achieve 208 subjects completing both treatment periods of 3 months.. There will be a total of 12 study clinic visits conducted on an outpatient basis. Subjects who meet the eligibility criteria at Screening (Visit 1) will complete a 12 to 21 day run-in period followed by two 12-week treatment periods that are separated by a 14 day wash-out. Clinic visits will be conducted at Screening (Visit 1), twice during the run-in period (Visits 2 and 3), at randomization (Visit 4) and three times during the first treatment period, on Treatment Day 2 (Visit 5) and at 6 and 12 weeks (Visits 6 and 7 respectively). During the washout period of 14 days there will be 2 clinic visits (Visits 8 and 9). During the second treatment period there will be 3 clinic visits, on Treatment Day 2 (Visit 10) and at 6 and 12 weeks (Visits 11 and 12 respectively). A Safety Follow-Up assessment (Visit 13) to record adverse events will be conducted by telephone 7 days after the end of the second treatment period or early withdrawal. Efficacy measurements will include pre and post dose FEV1, lung volume measurements and exercise endurance time measured using the endurance shuttle walking test (ESWT). Oxycon mobile measurements will be conducted in a subgroup of approximately 104 patients to investigate cardio respiratory measures during exercise. Safety and tolerability will be assessed by collection of adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), clinical laboratory tests and incidence of COPD exacerbations. Dyspnea will be assessed using the Exercise Dyspnea Scale (EDS), a patient-reported outcome. Blood samples will also be collected for potential pharmacogenetics analysis

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: Outpatient.
  • : A signed and dated written informed consent prior to study participation.
  • Age: 40 years of age or older at Visit 1.
  • Gender: Male or female subjects.
  • Diagnosis: An established clinical history of in accordance with the definition by the American Thoracic Society/European Respiratory Society [Celli, 2004]
  • Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ≥ 10 pack-years
  • Severity of Disease: A post-albuterol/salbutamol /FVC ratio of \<0.70 and a post-albuterol/salbutamol FEV1 of >35% and \<70% of predicted normal
  • Dyspnea: A score of ≥2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at Visit 1
  • Resting Lung Volumes: A resting FRC of ≥120% of predicted normal FRC at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: A current diagnosis of asthma.
  • Other Respiratory Disorders: Known respiratory disorders other than including but not limited to alpha-1 antitrypsin deficiency, active tuberculosis, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, and interstitial lung disease. Allergic rhinitis is not exclusionary.
  • Other Diseases/Abnormalities: Subjects with historical or current evidence of cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \< 5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study. Any physical or mental abnormality which would affect the patient carrying out exercise tests including peripheral vascular disease should be excluded at the investigators discretion.
  • Chest X-Ray: A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Visit 1 if a chest X-ray or CT scan is not available within 6 months prior to Visit 1. For subjects in Germany, if a chest X-ray (or CT scan) is not available in the 6 months prior to Visit 1 the subject will not be eligible for the study.
  • : A history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic.
  • Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
  • Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).
  • 12-Lead : An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1, including the presence of a paced rhythm on a 12-lead electrocardiogram (ECG) which causes the underlying rhythm and ECG to be obscured. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility.
  • Screening Labs: Significantly abnormal finding from clinical chemistry and hematology tests at Visit 1.
  • Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
  • Medications prior to Screening, including depot,oral , combinations of LABA/ICS, LABA, PDE4 inhibitors.
  • Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., \<12 hours per day) is not exclusionary.
  • Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy
  • Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
  • Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
  • Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
349 participants (actual)

Study arms

  • Experimental
    GSK 573719 + GW642444 125/25

    125mcg/25mcg nDPI

    Drug: GSK573719 + GW642444 62.5/25 · Drug: GSK 573719 125 · Drug: GW642444 25 · Drug: Plb

  • Experimental
    GSK 573719 +GW642444 62.5/25

    62.5mcg/25mcg nDPI

    Drug: GSK 573719 +GW642444 125/25 · Drug: GSK 573719 62.5 · Drug: GW642444 25 · Drug: Plb

  • Experimental
    GSK 573719 125

    125mcg nDPI

    Drug: GSK 573719 +GW642444 125/25 · Drug: Plb

  • Experimental
    GSK 573719 62.5

    62.5 mcg nDPI

    Drug: GSK573719 + GW642444 62.5/25 · Drug: GW642444 25 · Drug: Plb

  • Experimental
    GW 642444 25

    25mcg nDPI

    Drug: GSK 573719 +GW642444 125/25 · Drug: GSK573719 + GW642444 62.5/25 · Drug: Plb

  • Placebo comparator
    Plb

    Plb nDPI

    Drug: GSK 573719 +GW642444 125/25 · Drug: GSK573719 + GW642444 62.5/25 · Drug: GSK 573719 125 · Drug: GSK 573719 62.5

Interventions

  • DrugGSK 573719 +GW642444 125/25

    125mcg/ 25mcg

    Also known as: High Dose Dual

  • DrugGSK573719 + GW642444 62.5/25

    62.5mcg/25mcg

    Also known as: Low Dose Dual

  • 125mcg

    Also known as: High Dose 719

  • 62.5mcg

    Also known as: Low Dose 719

  • 25mcg

    Also known as: LABA (444)

  • DrugPlb

    Comparator

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

    Exercise endurance time (EET) post-dose at Week 12 is defined as the EET obtained 3 hours after dosing at Week 12. EET was measured using the externally paced field walking test called the endurance shuttle walk test (ESWT). Analysis performed using a repeated measures model with covariates of period walking speed, mean walking speed, period, treatment, visit, smoking status, center group, visit by period walking speed, visit by mean walking speed and visit by treatment interactions. The model used all available 3-hour post-dose change from baseline EET values recorded on Day 2, Week 6 and Week 12. Baseline was the EET assessment obtained prior to dosing on Day 1 of each period. The mean walking speed for each participant is the mean of the levels used for the ESWT in each of the two treatment periods. The period walking speed for each participant and treatment period is the difference between the level for that participant and period and the mean walking speed for that participant.

    Time frame: Week 12 of each treatment period (up to Study Week 29)

  2. Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 24 hours after dosing on Treatment Day 84. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions.

    Time frame: Week 12 of each treatment period (up to Study Week 29)

Secondary outcomes

  1. Change From Baseline in Inspiratory Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

    Inspiratory capacity (IC) is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Baseline is the IC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough IC is measured pre-dose on Treatment Week 12 of each treatment period. IC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12 of each treatment period. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. IC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

    Time frame: Week 12 of each treatment period (up to Study Week 29)

  2. Change From Baseline in Functional Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

    Functional Residual Capacity (FRC) is defined as the amount of air still left in the lungs after breathing out normally. Baseline is the FRC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough FRC is measured pre-dose on Treatment Week 12. FRC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. FRC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

    Time frame: Week 12 of each treatment period (up to Study Week 29)

  3. Change From Baseline in Residual Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

    Residual Volume (RV) is defined as the air that remains in the lungs after breathing out as fully as possible. Baseline is the RV value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough RV is measured pre-dose on Treatment Week 12. RV 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. RV measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

    Time frame: Week 12 of each treatment period (up to Study Week 29)

  4. Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period

    FEVI is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit post-dose FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 3 hours after dosing on Treatment Day 85. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions 3 hour post-dose FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12.

    Time frame: Week 12 of each treatment period (up to Study Week 29)

07

Results

Posted Feb 10, 2014

Participant flow

Participants (par.) who were eligible completed a 12- to 21-day Run-in Period followed by two 12-week treatment periods.

Treatment Period 1 (12 Weeks)
Participant flow — Treatment Period 1 (12 Weeks)
MilestonePlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC 125/25 µg QD
Started942628418178
Completed832125336772
Not completed11538146
Withdrew: Adverse event311352
Withdrew: Lack of efficacy611162
Withdrew: Protocol violation000101
Withdrew: Met protocol- defined stopping criteria010020
Withdrew: Lost to follow-up200101
Withdrew: Withdrawal by subject021210
Washout Period (14 Days)
Participant flow — Washout Period (14 Days)
MilestonePlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC 125/25 µg QD
Started832125336772
Completed822025326668
Not completed110114
Withdrew: Adverse event110112
Withdrew: Lack of efficacy000001
Withdrew: Withdrawal by subject000001
Treatment Period 2 (12 Weeks)
Participant flow — Treatment Period 2 (12 Weeks)
MilestonePlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC 125/25 µg QD
Started762322357166
Completed652219306359
Not completed1113587
Withdrew: Adverse event501110
Withdrew: Lack of efficacy511234
Withdrew: Protocol violation100010
Withdrew: Met protocol defined stopping criteria000110
Withdrew: Lost to follow-up001112
Withdrew: Withdrawal by subject000011

Outcome measures

PrimaryChange From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period

Exercise endurance time (EET) post-dose at Week 12 is defined as the EET obtained 3 hours after dosing at Week 12. EET was measured using the externally paced field walking test called the endurance shuttle walk test (ESWT). Analysis performed using a repeated measures model with covariates of period walking speed, mean walking speed, period, treatment, visit, smoking status, center group, visit by period walking speed, visit by mean walking speed and visit by treatment interactions. The model used all available 3-hour post-dose change from baseline EET values recorded on Day 2, Week 6 and Week 12. Baseline was the EET assessment obtained prior to dosing on Day 1 of each period. The mean walking speed for each participant is the mean of the levels used for the ESWT in each of the two treatment periods. The period walking speed for each participant and treatment period is the difference between the level for that participant and period and the mean walking speed for that participant.

Time frame:
Week 12 of each treatment period (up to Study Week 29)
Reported as:
Least squares mean · Seconds
Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period
SecondsPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period36.7 ± 13.1763.2 ± 23.9349.8 ± 23.7726.7 ± 19.7258.6 ± 13.8269.1 ± 13.99
Statistical analysis
  • Placebo vs UMEC 62.5 µg QD · Mixed Models Analysis · p = 0.321 (Nominal p-value) · Least squares mean difference: 26.5 · 95% CI -25.9 to 78.9Least square mean change difference=UMEC 62.5 µg minus Placebo.
  • Placebo vs UMEC 125 µg QD · Mixed Models Analysis · p = 0.620 (Nominal p-value) · Least squares mean difference: 13.1 · 95% CI -38.9 to 65.1Least square mean change difference=UMEC 125 µg minus Placebo.
  • Placebo vs VI 25 µg QD · Mixed Models Analysis · p = 0.665 (Nominal p-value) · Least squares mean difference: -10.0 · 95% CI -55.5 to 35.4Least square mean change difference=VI 25 µg minus Placebo.
  • UMEC 62.5 µg QD vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = 0.865 (Nominal p-value) · Least squares mean difference: -4.6 · 95% CI -57.6 to 48.4Least square mean change difference=UMEC/VI 62.5/25 µg minus UMEC 62.5 µg.
  • VI 25 µg QD vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = 0.174 (Nominal p-value) · Least squares mean difference: 31.9 · 95% CI -14.1 to 77.9Least square mean change difference=UMEC/VI 62.5/25 µg minus VI 25 µg.
  • UMEC 125 µg QD vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = 0.472 (Nominal p-value) · Least squares mean difference: 19.3 · 95% CI -33.4 to 71.9Least square mean change difference=UMEC/VI 125/25 µg minus UMEC 125 µg.
  • VI 25 µg QD vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = 0.072 (Nominal p-value) · Least squares mean difference: 42.4 · 95% CI -3.8 to 88.7Least square mean change difference=UMEC/VI 125/25 µg minus VI 25 µg.
  • Placebo vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = 0.234 (Nominal p-value) · Least squares mean difference: 21.9 · 95% CI -14.2 to 58.0Least square mean change difference=UMEC/VI 62.5/25 µg minus Placebo.
  • Placebo vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = 0.080 (Nominal p-value) · Least squares mean difference: 32.4 · 95% CI -3.9 to 68.8Least square mean change difference=UMEC/VI 125/25 µg minus Placebo.
PrimaryChange From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 24 hours after dosing on Treatment Day 84. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions.

Time frame:
Week 12 of each treatment period (up to Study Week 29)
Reported as:
Least squares mean · Liters
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period
LitersPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period-0.032 ± 0.01490.054 ± 0.02640.108 ± 0.02630.067 ± 0.02180.178 ± 0.01560.136 ± 0.0158
Statistical analysis
  • Placebo vs UMEC 62.5 µg QD · Mixed Models Analysis · p = 0.003 (Nominal p-value) · Least squares mean difference: 0.087 · 95% CI 0.030 to 0.143Least square mean change difference=UMEC 62.5 µg minus Placebo.
  • Placebo vs UMEC 125 µg QD · Mixed Models Analysis · p = <0.001 (Nominal p-value) · Least squares mean difference: 0.140 · 95% CI 0.084 to 0.196Least square mean change difference=UMEC 125 µg minus Placebo.
  • Placebo vs VI 25 µg QD · Mixed Models Analysis · p = <0.001 (Nominal p-value) · Least squares mean difference: 0.099 · 95% CI 0.050 to 0.148Least square mean change difference=VI 25 µg minus Placebo.
  • UMEC 62.5 µg QD vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = <0.001 (Nominal p-value) · Least squares mean difference: 0.124 · 95% CI 0.067 to 0.181Least square mean change difference=UMEC/VI 62.5/25 µg minus UMEC 62.5 µg.
  • VI 25 µg QD vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = <0.001 (Nominal p-value) · Least squares mean difference: 0.111 · 95% CI 0.062 to 0.161Least square mean change difference=UMEC/VI 62.5/25 µg minus VI 25 µg.
  • UMEC 125 µg QD vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = 0.320 (Nominal p-value) · Least squares mean difference: 0.029 · 95% CI -0.028 to 0.086Least square mean change difference=UMEC/VI 125/25 µg minus UMEC 125 µg.
  • VI 25 µg QD vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = 0.007 (Nominal p-value) · Least squares mean difference: 0.070 · 95% CI 0.019 to 0.120Least square mean change difference=UMEC/VI 125/25 µg minus VI 25 µg.
  • Placebo vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = <0.001 (Nominal p-value) · Least squares mean difference: 0.211 · 95% CI 0.172 to 0.249Least square mean change difference=UMEC/VI 62.5/25 µg minus Placebo.
  • Placebo vs UMEC/VI 125/25 µg QD · Mixed Models Analysis · p = <0.001 (Nominal p-value) · Least squares mean difference: 0.169 · 95% CI 0.129 to 0.209Least square mean change difference=UMEC/VI 125/25 µg minus Placebo.
SecondaryChange From Baseline in Inspiratory Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

Inspiratory capacity (IC) is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Baseline is the IC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough IC is measured pre-dose on Treatment Week 12 of each treatment period. IC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12 of each treatment period. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. IC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

Time frame:
Week 12 of each treatment period (up to Study Week 29)
Reported as:
Least squares mean · Liters
Change From Baseline in Inspiratory Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
LitersPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Trough-0.002 ± 0.02550.025 ± 0.04570.187 ± 0.04570.067 ± 0.03770.196 ± 0.02690.168 ± 0.0270
3-hours post-dose0.028 ± 0.02590.142 ± 0.04630.249 ± 0.04620.160 ± 0.03820.267 ± 0.02740.250 ± 0.0275
SecondaryChange From Baseline in Functional Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

Functional Residual Capacity (FRC) is defined as the amount of air still left in the lungs after breathing out normally. Baseline is the FRC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough FRC is measured pre-dose on Treatment Week 12. FRC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. FRC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

Time frame:
Week 12 of each treatment period (up to Study Week 29)
Reported as:
Least squares mean · Liters
Change From Baseline in Functional Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
LitersPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Trough0.020 ± 0.0494-0.262 ± 0.0899-0.241 ± 0.0890-0.109 ± 0.0738-0.219 ± 0.0523-0.350 ± 0.0524
3-hours post-dose-0.081 ± 0.0495-0.358 ± 0.0893-0.456 ± 0.0885-0.229 ± 0.0734-0.384 ± 0.0523-0.548 ± 0.0526
SecondaryChange From Baseline in Residual Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period

Residual Volume (RV) is defined as the air that remains in the lungs after breathing out as fully as possible. Baseline is the RV value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough RV is measured pre-dose on Treatment Week 12. RV 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. RV measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.

Time frame:
Week 12 of each treatment period (up to Study Week 29)
Reported as:
Least squares mean · Liters
Change From Baseline in Residual Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
LitersPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Trough0.039 ± 0.0521-0.337 ± 0.0948-0.249 ± 0.0940-0.138 ± 0.0779-0.255 ± 0.0552-0.432 ± 0.0553
3-hours post-dose-0.086 ± 0.0526-0.375 ± 0.0955-0.451 ± 0.0945-0.253 ± 0.0784-0.437 ± 0.0556-0.625 ± 0.0560
SecondaryChange From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period

FEVI is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit post-dose FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 3 hours after dosing on Treatment Day 85. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions 3 hour post-dose FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12.

Time frame:
Week 12 of each treatment period (up to Study Week 29)
Reported as:
Least squares mean · Liters
Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period
LitersPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period-0.007 ± 0.01590.122 ± 0.02770.156 ± 0.02750.115 ± 0.02290.254 ± 0.01660.217 ± 0.0169

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs), defined as those events occuring while participants were on treatment up until one day after the last dose (up to Week 33), are reported.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—6/170 (3.5%)18/170 (10.6%)
UMEC 62.5 µg QD—0/49 (0%)1/49 (2%)
UMEC 125 µg QD—3/50 (6%)5/50 (10%)
VI 25 µg QD—7/76 (9.2%)7/76 (9.2%)
UMEC/VI 62.5/25 µg QD—4/152 (2.6%)8/152 (5.3%)
UMEC/VI 125/25 µg QD—4/144 (2.8%)8/144 (5.6%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1700/491/500/760/1520/144
DeathGeneral disorders0/1700/491/500/760/1520/144
Type 2 diabetes mellitusMetabolism and nutrition disorders0/1700/491/500/760/1520/144
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1700/490/501/760/1520/144
PneumoniaInfections and infestations0/1700/490/501/760/1521/144
Bundle branch block leftCardiac disorders0/1700/490/501/760/1520/144
Non-cardiac chest painGeneral disorders1/1700/490/501/760/1520/144
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1700/490/501/760/1520/144
Ankle fractureInjury, poisoning and procedural complications0/1700/490/501/760/1520/144
CataractEye disorders0/1700/490/501/760/1520/144
Most frequent other events
Most frequent other events
EventPlaceboUMEC 62.5 µg QDUMEC 125 µg QDVI 25 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QD
NasopharyngitisInfections and infestations10/1701/491/503/765/1528/144
HeadacheNervous system disorders7/1700/491/504/763/1522/144
SinusitisInfections and infestations3/1700/492/500/760/1524/144
Dry mouthGastrointestinal disorders0/1700/492/500/760/1520/144

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Study Treatments
Mean61.6 ± 8.25
Sex: Female, Male
Sex: Female, Male(Participants)All Study Treatments
Female153
Male195
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Study Treatments
African American/African Heritage11
White - White/Caucasian/European Heritage336
Mixed Race1
08

Study locations

31 sites
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    Lebanon, New Hampshire 03756, United States
  • GSK Investigational Site
    Albany, New York 12205, United States
  • GSK Investigational Site
    Columbus, Ohio 43215, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    Kingwood, Texas 77339, United States
  • GSK Investigational Site
    Richmond, Virginia 23229, United States
  • GSK Investigational Site
    Plovdiv, 4000, Bulgaria
  • GSK Investigational Site
    Sofia, 1000, Bulgaria
  • GSK Investigational Site
    Tallinn, 13619, Estonia
  • GSK Investigational Site
    Tartu, 51014, Estonia
  • GSK Investigational Site
    Gelnhausen, Hessen 63571, Germany
  • GSK Investigational Site
    Wiesbaden, Hessen 65187, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44787, Germany
  • GSK Investigational Site
    Solingen, Nordrhein-Westfalen 42651, Germany
  • GSK Investigational Site
    Witten, Nordrhein-Westfalen 58452, Germany
  • GSK Investigational Site
    Grosshansdorf, Schleswig-Holstein 22927, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Hamburg, 20253, Germany
  • GSK Investigational Site
    Hamburg, 20354, Germany
  • GSK Investigational Site
    Barnaul, 656 045, Russian Federation
  • GSK Investigational Site
    Chelyabinsk, 454106, Russian Federation
  • GSK Investigational Site
    Moscow, 105 077, Russian Federation
  • GSK Investigational Site
    Moscow, 127018, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 197022, Russian Federation
  • GSK Investigational Site
    Northwood, Middlesex HA6 2RN, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 8 months after primary completion. A results delay was requested in Dec 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2011
First posted
Apr 4, 2011
Start
Mar 1, 2011
Primary completionActual
Jun 1, 2012
CompletionActual
Jun 14, 2012
Results delay requested
Dec 13, 2012
Results first posted
Feb 10, 2014
Last update
Oct 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01328444
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 4, 2011
Start date
Mar 1, 2011
Primary completion
Jun 1, 2012
Completion
Jun 14, 2012
Results posted
Feb 10, 2014
Last update
Oct 11, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vilanterol

Start the discussion